Author:
Conde Esther,Hernandez Susana,Martinez Rebeca,Angulo Barbara,De Castro Javier,Collazo-Lorduy Ana,Jimenez Beatriz,Muriel Alfonso,Mate Jose Luis,Moran Teresa,Aranda Ignacio,Massuti Bartomeu,Rojo Federico,Domine Manuel,Sansano Irene,Garcia Felip,Felip Enriqueta,Mancheño Nuria,Juan Oscar,Sanz Julian,Gonzalez-Larriba Jose Luis,Atienza-Cuevas Lidia,Arriola-Arellano Esperanza,Abdulkader Ihab,Garcia-Gonzalez Jorge,Camacho Carmen,Rodriguez-Abreu Delvys,Teixido Cristina,Reguart Noemi,Gonzalez-Piñeiro Ana,Lazaro-Quintela Martin,Lozano Maria Dolores,Gurpide Alfonso,Gomez-Roman Javier,Lopez-Brea Marta,Pijuan Lara,Salido Marta,Arriola Edurne,Company Amparo,Insa Amelia,Esteban-Rodriguez Isabel,Saiz Monica,Azkona Eider,Alvarez Ramiro,Artal Angel,Plaza Maria Luz,Aguiar David,Enguita Ana Belen,Benito Amparo,Paz-Ares Luis,Garrido Pilar,Lopez-Rios Fernando
Funder
Bristol-Myers Squibb
Novartis
Roche
Pfizer
Guardant Health and Sysmex
AbbVie
Thermo Fisher Scientific
Instituto de Salud Carlos III
Comunidad de Madrid
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference45 articles.
1. Crizotinib in ROS1-rearranged non–small-cell lung cancer;Shaw;N Engl J Med,2014
2. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort;Mazières;J Clin Oncol,2015
3. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial;Shaw;Lancet Oncol,2017
4. Drilon A, Siena S, Ou S-HI, et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov.
5. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement;Lim;J Clin Oncol,2017